We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




DNA Test Assesses Risk of Malignant Hyperthermia

By LabMedica International staff writers
Posted on 14 Nov 2011
A molecular test may make it much simpler to identify patients at risk of malignant hyperthermia (MH) a life-threatening complication of exposure to anesthetics. More...


The new technique, called high resolution melting (HRM) curve analysis, provides a sensitive and specific tool for the identification of genetic variants responsible for MH and a much simpler alternative to currently available tests.

At Skåne University Hospital Lund (Malmö, Sweden) scientists developed an approach to assessing the risk of MH by using a sample of DNA extracted from a blood sample. Fragments of DNA from the ryanodine receptor 1 (RYR1) gene are identified and gradually heated to assess the temperature at which the strands of DNA begin to unwind. Fragments with unusual, or aberrant melting profiles can undergo full gene sequencing to pinpoint specific variants potentially causing MH.

The scientists evaluated the HRM curve analysis approach in 16 MH susceptible patients. All had either experienced a life-threatening episode of MH themselves, had a close relative who had died of MH, or had undergone the muscle biopsy test for suspected abnormalities. A total of approximately 2,500 DNA fragments underwent HRM curve analysis. The test showed significantly aberrant melting profiles in 21% of the DNA fragments tested. Subsequent gene sequencing studies identified 131 variants known to cause MH, along with 17 known or suspected mutations. Overall, 13 of the 16 MH-susceptible patients had genetic abnormalities known or suspected of causing MH, which is a rate of 81%. The use of HRM curve analysis to look for MH-related mutations of the RYR1 gene would greatly reduce the need for in-depth gene sequencing studies, without sacrificing test sensitivity.

Malignant hyperthermia is a rare condition in which genetically susceptible people develop rapid increases in body temperature and muscle rigidity in response to certain anesthetics and other drugs. Once the condition is recognized, it can generally be avoided by substituting other anesthetics. However, susceptible patients generally go unrecognized until they or a family member experience an episode of MH. The study was published in the November 2011 edition of the journal Anesthesia & Analgesia.

Related Links:
Skåne University Hospital



Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Capillary Blood Collection Tube
IMPROMINI M3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.